[1] Hiligsmann M, Cooper C, Arden N, et al. Health economics in the field of osteoarthritis: an expert’s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2013; 43: 303–313[2] Goldring MB, Berenbaum F. Emerging targets in osteoarthritis therapy. Curr Opin Pharmacol. 2015; 22: 51-63.[3] Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci. 2010;1192:230-237.[4] Musumeci G, Castrogiovanni P, Trovato FM, et al. Biomarkers of Chondrocyte Apoptosis and Autophagy in Osteoarthritis. Int J Mol Sci. 2015;16(9): 20560-20575.[5] Blanco FJ. Osteoarthritis year in review 2014: we need more biochemical biomarkers in qualification phase. Osteoarthritis Cartilage. 2014; 22(12):2025-2032.[6] Troeberg L, Nagase H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta. 2012; 1824(1):133-145.[7] Buckwalter JA, Mankin HJ, Grodzinsky AJ. Articular cartilage and osteoarthritis. Instr Course Lect. 2005; 54: 465-480.[8] Vincent TL. Targeting mechanotransduction pathways in osteoarthritis: a focus on the pericellular matrix. Curr Opin Pharmacol. 2013;13: 449-454.[9] Matsui Y, Iwasaki N, Kon S, et al. Accelerated development of aging-associated and instability-induced osteoarthritis in osteopontin-deficient mice. Arthritis Rheum. 2009; 60: 2362-2371.[10] Sharif SA, Du X, Myles T, et al. Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum. 2009;60: 2902-2912.[11] Denhardt DT, Giachelli CM , Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol .2001;41: 723-749.[12] Chen YJ, Shen JL, Wu CY, et al. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol.2009; 60: 225-230.[13] Zeng C, Gao SG, Lei GH. Response to OPN gene polymorphisms influence the risk of knee OA and OPN levels in synovial fluid in a Chinese population. Arthritis Res Ther. 2014; 16(5):433.[14] Gao SG, Zeng C, Song Y, et al. Effect of osteopontin on the mRNA expression of ADAMTS4 and ADAMTS5 in chondrocytes from patients with knee osteoarthritis.Exp Ther Med. 2015; 9(5):1979-1983. [15] Zhang FJ, Yu WB, Luo W, et al. Effect of osteopontin on TIMP-1 and TIMP-2 mRNA in chondrocytes of human knee osteoarthritis in vitro.Exp Ther Med. 2014; 8(2):391-394.[16] Kevorkian L, Young DA, Darrah C, at al. Expression pro?ling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum. 2004; 50(1):131-141.[17] Chen D, Shen J, Zhao W, et al. Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone Res. 2017 Jan 17; 5:16044.[18] Martel-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016; 2:16072.[19] Findlay DM, Kuliwaba JS. Bone-cartilage crosstalk: a conversation for understanding osteoarthritis. Bone Res. 2016; 4:16028.[20] Dorotka R, Bindreiter U, Vavken P, et al. Behavior of human articular chondrocytes derived from nonarthritic and osteoarthritic cartilage in a collagen matrix. Tissue Eng. 2005; 11(5-6):877-886.[21] Legendre F, Bogdanowicz P, Martin G, et al. Rhein, a diacerhein-derived metabolite, modulates the expression of matrix degrading enzymes and the cell proliferation of articular chondrocytes by inhibiting ERK and JNK-AP-1 dependent pathways. Clin Exp Rheumatol. 2007; 25(4):546-555.[22] Tetlow LC, Woolley DE. Histamine stimulates the proliferation of human articular chondrocytes in vitro and is expressed by chondrocytes in osteoarthritic cartilage. Ann Rheum Dis. 2003; 62(10):991-994.[23] De Fusco C, Messina A, Monda V, et al. Osteopontin: relation between adipose tissue and bone homeostasis. Stem Cells Int. 2017; 2017:4045238.[24] Clemente N, Raineri D, Cappellano G, et al. Osteopontin bridging innate and adaptive immunity in autoimmune diseases. J Immunol Res. 2016; 2016:7675437.[25] Shi L, Wang X. Role of osteopontin in lung cancer evolution and heterogeneity. Semin Cell Dev Biol. 2017;64:40-47.[26] Gao SG, Li KH, Zeng KB, et al. Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients. Osteoarthritis Cartilage. 2010; 18(1):82-87.[27] Honsawek S, Tanavalee A, Sakdinakiattikoon M, et al. Correlation of plasma and synovial fluid osteopontin with disease severity in knee osteoarthritis. Clin Biochem. 2009; 42(9):808-812.[28] Hasegawa M, Segawa T, Maeda M, et al. Thrombin-cleaved osteopontin levels in synovial fluid correlate with disease severity of knee osteoarthritis. J Rheumatol. 2011; 38(1):129-134.[29] 姜未,雷光华,林博文,等. 骨桥蛋白(OPN)对人膝骨关节炎软骨细胞MMP-13表达的影响[J]. 中国修复重建外科杂志, 2014 , 28(11):1342-1345.[30] Li YS, Jiang W, Wang H, et al. Osteopontin promotes expression of matrix metalloproteinase 13 through NF-kappaB signaling in osteoarthritis. Biomed Res Int, 2016; 2016:6345656. |